ESOI - ESSO Webinar: Tumour board: GEP-NET
29 May, 2020 - Open
This joint ESOI-ESSO webinar, taking place at 18:00 CET on Friday 29th May, will be given by a team of experts in Neuroendocrine tumors, in particular a multidisciplinary meeting among radiologists, gastroenterologists and a surgeon will simulated in this online lecture.
Neuroendocrine tumors (NETs) are considered as rare neoplasms, but their incidence and prevalence are increasing due to their naturally indolent behavior as well as increased detection with improved imaging techniques. Two thirds can be found in the gastrointestinal and pancreatic tract and one third in the lungs. The diagnosis is based on incidental imaging findings or clinical in the case of functional NETs. It is important to know the typical findings of neuroendocrine tumors to prevent misdiagnosis. The role of Imaging in diagnosis, staging and characterizing NETs is crucial. NETs usually demonstrate hyper-enhancement in the arterial phase both primary and metastatic lesions. CT is considered as the first line in NETs diagnosis for its high sensitivity. MR has a specific role in diagnosis of pancreatic neuroendocrine tumors and in detection of liver metastases. The role of nuclear medicine (PET 68-Ga-DOTANOC and 18F-FDG PET) is remarkable in its ability to supply a specific diagnosis due to the aberrant expression of somatostatin receptors in most of NETs. In particular, all patients with diagnosis or high suspicion of NETs underwent 68-Ga-DOTANOC to evaluate the somatostatin receptors and possibility to take advantage of radionuclide therapy. While, 18F-FDG PET has a prognostic role in identifying patients with high metabolism and poorly differentiated NETs. Finally, the therapeutic options are mainly based on imaging staging, grading system and proliferative index (Ki67).
This webinar is open to ESSO members, please register on the below link, once your membership has been confirmed you will recieve a link for the webinar.